188 related articles for article (PubMed ID: 23216610)
1. Central and effector memory CD4 and CD8 T-cell responses to tumor-associated antigens.
Caserta S; Borger JG; Zamoyska R
Crit Rev Immunol; 2012; 32(2):97-126. PubMed ID: 23216610
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.
Church SE; Jensen SM; Antony PA; Restifo NP; Fox BA
Eur J Immunol; 2014 Jan; 44(1):69-79. PubMed ID: 24114780
[TBL] [Abstract][Full Text] [Related]
3. Understanding memory CD8
Samji T; Khanna KM
Immunol Lett; 2017 May; 185():32-39. PubMed ID: 28274794
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
Wang LX; Chen BG; Plautz GE
J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
[TBL] [Abstract][Full Text] [Related]
5. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
Reiser J; Banerjee A
J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
[TBL] [Abstract][Full Text] [Related]
6. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
7. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
8. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells.
Trella E; Raafat N; Mengus C; Traunecker E; Governa V; Heidtmann S; Heberer M; Oertli D; Spagnoli GC; Zajac P
Eur J Immunol; 2016 Feb; 46(2):420-31. PubMed ID: 26561341
[TBL] [Abstract][Full Text] [Related]
10. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
Jenq RR; Curran MA; Goldberg GL; Liu C; Allison JP; van den Brink MR
PLoS One; 2012; 7(4):e35222. PubMed ID: 22493742
[TBL] [Abstract][Full Text] [Related]
11. Vaccines targeting helper T cells for cancer immunotherapy.
Melssen M; Slingluff CL
Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541
[TBL] [Abstract][Full Text] [Related]
12. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
13. A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Yong CS; John LB; Devaud C; Prince MH; Johnstone RW; Trapani JA; Darcy PK; Kershaw MH
Oncotarget; 2016 Jun; 7(23):34582-98. PubMed ID: 27153556
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.
Nesbeth YC; Martinez DG; Toraya S; Scarlett UK; Cubillos-Ruiz JR; Rutkowski MR; Conejo-Garcia JR
J Immunol; 2010 May; 184(10):5654-62. PubMed ID: 20400704
[TBL] [Abstract][Full Text] [Related]
15. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.
Jing W; Gershan JA; Johnson BD
Blood; 2009 Apr; 113(18):4449-57. PubMed ID: 19182203
[TBL] [Abstract][Full Text] [Related]
16. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model.
Satooka H; Ishigaki H; Todo K; Terada K; Agata Y; Itoh Y; Ogasawara K; Hirata T
Sci Rep; 2020 May; 10(1):8414. PubMed ID: 32439888
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
19. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.
Fallarino F; Grohmann U; Bianchi R; Vacca C; Fioretti MC; Puccetti P
J Immunol; 2000 Nov; 165(10):5495-501. PubMed ID: 11067902
[TBL] [Abstract][Full Text] [Related]
20. Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
Pathangey LB; McCurry DB; Gendler SJ; Dominguez AL; Gorman JE; Pathangey G; Mihalik LA; Dang Y; Disis ML; Cohen PA
Oncotarget; 2017 Feb; 8(7):10785-10808. PubMed ID: 27974697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
